IP Library Granted Patent US 9,469,867
Granted Patent B2
US 9,469,867 · App. 12/800,633 · Granted Oct 18, 2016

DNA glycosylase/lyase and AP endonuclease substrates

Inventors: Olaf Piepenburg (Cambridge, GB); Niall A. Armes (Essex, GB)
Assignee: Alere San Diego, Inc.
C12Q1/6816
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,469,867
App. No.
12/800,633
Granted
Oct 18, 2016
Kind
B2
Abstract

A new class of nucleic acid substrates for AP endonucleases and members of the glycosylase/lyase family of enzymes is described. Representatives of each family, the enzymes Nfo and fpg, respectively, cleave nucleic acid backbones at positions in which a base has been replaced by a linker to which a variety of label moieties may be attached. The use of these synthetic substrates embedded within oligonucleotides is of utility in a number of applications.

Claims (55)

1. A process of detecting the presence or absence of a target nucleic acid, comprising the steps of:

(a) contacting an oligonucleotide probe to a target nucleic acid, thereby forming a complex between the probe and the target nucleic acid, wherein the probe comprises a dR-O—[C]n nucleotide that lacks a base and has a sugar with a carbon at a 1′ position, and wherein the carbon at the 1′ position is covalently linked through an oxygen atom to a carbon atom of a linker containing n carbon atoms wherein n is 1-8;

(b) contacting the probe/nucleic acid complex with a nuclease selected from the group consisting of AP endonuclease, DNA glycosylase/lyase and DNA glycosylase, wherein the nuclease can excise the linker from the complex and/or specifically cleave the probe at the dR-O—[C]n nucleotide; and

(c) detecting whether such excision or cleavage has occurred.

2. The process of claim 1 , wherein the target nucleic acid is the product of a nucleic acid amplification reaction.

3. The process of claim 2 , wherein the amplification reaction is monitored either

(i) in real time, or

(ii) at an endpoint for the reaction.

4. The process according to claim 2 , wherein the amplification reaction is

(i) a recombinase polymerase amplification process; or

(ii) a polymerase chain reaction.

5. The process of claim 1 , wherein step (a) comprises either:

(i). hybridizing the probe to the target nucleic acid; or

(ii) contacting the probe with a recombinase to form a recombinase/probe complex and contacting the recombinase/probe complex to the nucleic acid to form the probe/target nucleic acid complex.

6. The process of claim 1 , wherein the nuclease is endonuclease IV or 8-oxoguanine DNA glycosylase.

7. The process of claim 1 , wherein n is 3-6.

8. The process of claim 1 , wherein the probe is blocked at its 3′-end to prevent polymerase extension.

9. The process of claim 1 , wherein the linker is conjugated to a detectable label.

10. The process of claim 9 , wherein the detectable label is a fluorophore and the probe is further conjugated to a quencher, or the detectable label is a quencher and the probe is further conjugated to a fluorophore.

11. The process of claim 10 , wherein the quencher or fluorophore further conjugated to the probe is conjugated at one end of the probe.

12. The process of claim 9 , wherein the detectable label is selected from the group consisting of biotin, digoxygenin, peptide, fluorophore, quencher, antibody and a quantum dot.

13. The process of claim 10 , wherein nuclease activity excises and frees the fluorophore or quencher associated with the dR-O—[C]n residue and the detection step comprises measuring a difference, if any, in fluorescence between the conjugated and free state.

14. The process of claim 10 , wherein the fluorophore and quencher are separated by 4-6 bases.

15. The process of claim 4 , wherein the recombinase polymerase amplification process comprises:

(i) contacting a recombinase agent with a first and a second nucleic acid primer to form a first and a second nucleoprotein primer;

(ii) contacting the first and second nucleoprotein primers to a double stranded target sequence to form a first double stranded structure at a first portion of the first strand and to form a double stranded structure at a second portion of the second strand so the 3′ ends of the first nucleic acid primer and the second nucleic acid primer are oriented towards each other on a given template DNA molecule;

(iii) extending the 3′ end of the first and second nucleoprotein primers by DNA polymerases to generate first and second double stranded nucleic acids, and first and second displaced strands of nucleic acid;

and repeating (ii) and (iii) until a desired degree of amplification is reached.

16. The process of claim 4 , wherein the recombinase polymerase amplification is carried out in the presence of a crowding agent.

17. A process of cleaving an oligonucleotide in a complex with a nucleic acid, which comprises contacting the oligonucleotide/nucleic acid complex with a nuclease selected from the group consisting of AP endonuclease, DNA glycosylase/lyase and DNA glycosylase, wherein the oligonucleotide contains a dR-O—[C]n nucleotide that lacks a base and has a sugar with a carbon at a 1′ position, and wherein the carbon at the 1′ position is covalently linked through an oxygen atom to a carbon atom of a linker containing n carbon atoms wherein n is 1-8; and wherein the nuclease specifically cleaves the probe at the dR-O—[C]n nucleotide.

18. The process of claim 17 , wherein the nuclease is endonuclease IV or 8-oxoguanine DNA glycosylase.

19. The process of claim 17 , wherein n is 3-6.

20. The process of claim 17 , wherein the oligonucleotide is blocked at its 3′-end to prevent polymerase extension.

21. The process of claim 17 , wherein the linker is conjugated to a detectable label.

22. The process of claim 9 , wherein the detectable label is selected from the group consisting of biotin, digoxygenin, peptide, fluorophore, quencher, antibody and a quantum dot.

23. The process of claim 17 , wherein the process further comprises the step of contacting the oligonucleotide to the nucleic acid to form a oligonucleotide/nucleic acid complex, and optionally wherein:

(i) the target nucleic acid is the product of a nucleic acid amplification reaction;

(ii) contacting the oligonucleotide to the nucleic acid comprises hybridizing the oligonucleotide to the nucleic acid; or

(iii) contacting the oligonucleotide to the nucleic acid comprises contacting the oligonucleotide with a recombinase to form a recombinase/oligonucleotide complex and contacting the recombinase/oligonucleotide complex to the nucleic acid to form the oligonucleotide/nucleic acid complex.

24. The process of claim 20 , wherein the nucleic acid amplification reaction is

(i) a recombinase polymerase process; or

(ii) a polymerase chain reaction.

25. The process of claim 24 , wherein the recombinase polymerase amplification comprises process comprising the following steps:

(i) contacting a recombinase agent with a first and a second nucleic acid primer to form a first and a second nucleoprotein primer;

(ii) contacting the first and second nucleoprotein primers to a double stranded target sequence to form a first double stranded structure at a first portion of the first strand and to

form a double stranded structure at a second portion of the second strand so the 3′ ends of the first nucleic acid primer and the second nucleic acid primer are oriented towards each other on a given template DNA molecule;

(iii) extending the 3′ end of the first and second nucleoprotein primers by DNA polymerases to generate first and second double stranded nucleic acids, and first and second displaced strands of nucleic acid;

and repeating (ii) and (iii) until a desired degree of amplification is reached.

26. The process of claim 17 , further comprising detecting cleavage of the oligonucleotide, optionally wherein detection is monitored either

(i) in real time, or

(ii) at an endpoint for the reaction.

27. The process according to claim 26 , wherein either

(i) the linker is conjugated to a fluorophore and the oligonucleotide is further conjugated to a quencher; or

(ii) the linker is conjugated to a quencher and the oligonucleotide is further conjugated to a fluorophore; and optionally wherein nuclease activity excises and frees the fluorophore or quencher associated with the dR-O—[C]n residue and the detection step comprises measuring a difference, if any, in fluorescence between the conjugated and free state.

28. The process of claim 24 , wherein the recombinase polymerase amplification is carried out in the presence of a crowding agent.

Assignments (10)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2020
From: ALERE SAN DIEGO INC.
To: ABBOTT DIAGNOSTICS SCARBOROUGH, INC.
Reel/Frame 054604/0936 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498 Recorded Oct 5, 2017
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT
To: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
Reel/Frame 044213/0258 →
ASSIGNMENT OF IP SECURITY AGREEMENT, PREVIOUSLY RECORDED AT REEL 036994, FRAME 0192 Recorded Nov 16, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING ADMINISTRATIVE AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR ADMINISTRATIVE AGENT
Reel/Frame 037115/0498 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 29, 2015
From: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 036994/0192 →
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287 Recorded Jun 23, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
To: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL, INC.; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; MATRIA HEALTHCARE, INC.; ZYCARE, INC.
Reel/Frame 036011/0581 →
SECURITY AGREEMENT Recorded Jul 7, 2011
From: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL INCORPORATED; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; ZYCARE INC.; MARTIA HEALTHCARE, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 026557/0287 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2010
From: PIEPENBURG, OLAF; ARMES, NIALL A.
To: ALERE SAN DIEGO, INC.
Reel/Frame 025341/0345 →
CHANGE OF NAME Recorded Sep 30, 2010
From: ASM SCIENTIFIC, INC.
To: TWISTDX, INC.
Reel/Frame 025066/0515 →
CERTIFICATE OF MERGER Recorded Sep 30, 2010
From: TWISTDX, INC.
To: BIOSITE INCORPORATED
Reel/Frame 025066/0614 →
CHANGE OF NAME Recorded Sep 30, 2010
From: BIOSITE INCORPORATED
To: ALERE SAN DIEGO, INC.
Reel/Frame 025066/0698 →
Continuity (2)
Provisional Application 61179793 · May 20, 2009
Related Publication 20110053153A1 · Mar 3, 2011